Zhejiang Lanyu Digital Technology
301585
BBK Test Systems
301598
MEIZHIGAO
834765
Youkeshu Technology
300209
Hangzhou Raycloud Technology Co.,Ltd
688365
CN Stock MarketDetailed Quotes
000908 Hunan Jingfeng Pharmaceutical
- 4.36
- +0.16+3.81%
Market Closed Dec 20 15:00 CST
3.84BMarket Cap-13.42P/E (TTM)
4.40High4.17Low352.44KlotVolume4.25Open4.20Pre Close151.69MTurnover4.47%Turnover RatioLossP/E (Static)879.77MShares6.3652wk High-24.63P/B3.44BFloat Cap0.7252wk Low4.41Limit Up788.90MShs Float28.51Historical High3.99Limit Down5.48%Amplitude0.72Historical Low--Dividend TTM4.30Avg Price162.78KlotAsk--Div YieldTTM100Lot Size183.70KlotBid
Hunan Jingfeng Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Goods sale service render cash | -42.94%334.18M | -38.59%236.34M | -31.73%138.15M | -22.12%749.53M | -11.02%585.66M | -7.21%384.85M | 8.40%202.37M | -4.83%962.43M | -7.71%658.19M | -4.98%414.75M |
| Refunds of taxes and levies | ---- | ---- | ---- | --0 | ---- | ---- | ---- | 182,601.94%3.62M | 463,654.69%3.74M | 463,654.69%3.74M |
| Cash received relating to other operating activities | -43.23%31.27M | -51.19%14.77M | 73.03%9.58M | -19.60%58.85M | -26.86%55.08M | -1.49%30.27M | -37.33%5.54M | 59.12%73.2M | 198.64%75.3M | 36.09%30.72M |
| Cash inflows from operating activities | -42.96%365.44M | -39.51%251.11M | -28.94%147.73M | -22.22%808.38M | -13.09%640.74M | -7.59%415.11M | 6.33%207.91M | -1.71%1.04B | -0.16%737.22M | -2.15%449.21M |
| Goods services cash paid | 47.34%114.66M | 56.48%80.23M | 132.56%54.36M | -14.42%123.87M | -17.48%77.82M | 15.11%51.27M | 9.74%23.38M | 0.20%144.74M | -19.76%94.31M | -16.30%44.55M |
| Staff behalf paid | -40.45%64.78M | -34.00%45.06M | -34.45%23.77M | -17.34%131.64M | -7.02%108.78M | -8.26%68.27M | -9.30%36.27M | -23.37%159.26M | -24.70%116.99M | -30.43%74.41M |
| All taxes paid | -73.33%20.32M | -74.75%15.11M | -71.11%8.91M | 24.27%93.31M | 69.46%76.22M | 156.88%59.83M | 283.11%30.85M | -17.89%75.09M | -30.88%44.98M | -48.59%23.29M |
| Cash paid relating to other operating activities | -57.85%142.77M | -56.87%94.28M | -49.87%52.03M | -20.93%424.51M | -8.04%338.69M | -11.71%218.62M | -15.44%103.79M | 9.62%536.91M | 17.23%368.32M | 17.07%247.61M |
| Cash outflows from operating activities | -43.05%342.54M | -41.03%234.68M | -28.41%139.08M | -15.58%773.32M | -3.69%601.51M | 2.09%397.99M | 1.15%194.28M | -1.87%915.99M | -4.22%624.59M | -6.51%389.86M |
| Net cash flows from operating activities | -41.61%22.9M | -4.02%16.43M | -36.55%8.64M | -71.55%35.06M | -65.17%39.23M | -71.15%17.12M | 295.27%13.62M | -0.46%123.27M | 30.57%112.63M | 41.11%59.35M |
| Investing cash flow | ||||||||||
| Cash received from disposal of investments | ---- | ---- | ---- | -90.51%5.06M | -99.94%34.52K | -99.94%32.65K | ---- | 342.09%53.31M | 758.21%53.31M | 758.21%53.31M |
| Cash received from returns on investments | ---- | ---- | ---- | ---- | ---- | ---- | --18.32K | ---- | -99.92%2.76K | ---- |
| Net cash received from disposal of fix assets、 intangible assets 、other long-term asset | -95.46%177.8K | -94.09%177.9K | -84.79%171.8K | -93.65%7.51M | 131.11%3.92M | 80.45%3.01M | 25.42%1.13M | 885.10%118.33M | -73.64%1.69M | -10.42%1.67M |
| Net cash received from disposal of subsidiaries and other business units | --650.1K | ---- | ---- | --0 | ---- | ---- | ---- | -74.86%63.6M | -54.83%63.6M | -77.55%31.6M |
| Cash received relating to other investing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --0 | ---- |
| Cash inflows from investing activities | -79.05%827.9K | -94.16%177.9K | -85.04%171.8K | -94.66%12.57M | -96.67%3.95M | -96.48%3.04M | -98.66%1.15M | -24.21%235.25M | -27.96%118.61M | -43.11%86.58M |
| Cash paid to acquire fixed assets intangible assets and other long-term assets | -83.35%1.19M | -86.66%839.29K | -88.71%587.7K | -22.90%10.42M | 79.35%7.13M | 208.40%6.29M | 364.01%5.21M | -64.54%13.52M | -82.08%3.97M | -81.91%2.04M |
| Cash paid to acquire investments | --25K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Net cash paid to acquire subsidiaries and other business units | ---- | ---- | ---- | ---- | --8.81M | --6.2M | --1.2M | ---- | ---- | ---- |
| Cash paid relating to other investing activities | ---- | ---- | ---- | --11.52M | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash outflows from investing activities | -92.39%1.21M | -93.28%839.29K | -90.83%587.7K | 62.33%21.94M | 300.96%15.93M | 512.33%12.49M | 470.93%6.41M | -64.18%13.52M | -85.01%3.97M | -81.90%2.04M |
| Net cash flows from investing activities | 96.80%-383.68K | 93.00%-661.39K | 92.09%-415.9K | -104.22%-9.37M | -110.45%-11.98M | -111.17%-9.45M | -106.21%-5.26M | -18.68%221.73M | -17.01%114.64M | -40.00%84.54M |
| Financing cash flow | ||||||||||
| Cash received from capital contributions | --172.7K | --172.7K | ---- | 65.49%1.11M | ---- | ---- | ---- | -96.27%672K | ---- | ---- |
| Cash from borrowing | -87.87%19.1M | -95.59%6.5M | ---- | -8.87%158M | -9.25%157.4M | -6.23%147.4M | --138M | -42.95%173.38M | -44.92%173.45M | 2.07%157.19M |
| Cash received relating to other financing activities | ---- | ---- | ---- | ---- | --700K | --700K | ---- | -80.78%10.9M | --0 | --0 |
| Cash inflows from financing activities | -87.81%19.27M | -95.49%6.67M | --0 | -13.97%159.11M | -8.85%158.1M | -5.78%148.1M | --138M | -51.16%184.95M | -54.27%173.45M | -3.58%157.19M |
| Borrowing repayment | -88.50%20.86M | -93.69%10.35M | -98.95%1.5M | -61.76%173.71M | -46.87%181.38M | -34.78%164.04M | 72.49%142.14M | -22.40%454.23M | -25.83%341.41M | -16.02%251.51M |
| Dividend interest payment | -10.57%9.44M | -3.09%6.98M | -8.88%3.8M | -40.42%23.61M | -50.94%10.56M | -53.56%7.2M | -30.80%4.17M | -56.68%39.63M | -58.78%21.52M | -63.24%15.51M |
| Cash payments relating to other financing activities | 1,752.78%2.79M | 1,228.37%2M | ---- | 467.59%154.77M | -99.37%150.56K | -99.34%150.56K | -94.69%900K | -69.40%27.27M | -81.39%23.85M | -61.45%22.85M |
| Cash outflows from financing activities | -82.77%33.1M | -88.72%19.33M | -96.40%5.3M | -32.44%352.09M | -50.34%192.09M | -40.87%171.39M | 39.69%147.21M | -31.96%521.13M | -39.63%386.79M | -27.70%289.87M |
| Net cash flows from financing activities | 59.33%-13.82M | 45.67%-12.66M | 42.43%-5.3M | 42.60%-192.98M | 84.07%-33.99M | 82.44%-23.29M | 91.26%-9.21M | 13.19%-336.17M | 18.39%-213.34M | 44.24%-132.68M |
| Net cash flow | ||||||||||
| Exchange rate change effecting cash and cash equivalents | 2,249.16%32.92K | 1,149.16%21.24K | -159,745.73%-957.81K | -161.16%-92.48K | -70.27%1.4K | -22.19%1.7K | -236.71%-599.21 | 372.76%151.22K | 75.90%4.71K | 100.66%2.19K |
| Net increase in cash and cash equivalents | 229.39%8.73M | 120.08%3.14M | 332.42%1.97M | -1,964.78%-167.37M | -148.40%-6.75M | -239.31%-15.62M | 95.09%-846.71K | -2.13%8.98M | 137.67%13.94M | 120.28%11.21M |
| Add:Begin period cash and cash equivalents | -94.19%10.54M | -92.72%12.96M | -92.86%12.96M | 5.31%177.91M | 7.38%181.4M | 5.39%178.05M | 7.38%181.4M | 5.74%168.94M | 5.62%168.94M | 5.62%168.94M |
| End period cash equivalent | -88.97%19.27M | -90.09%16.09M | -91.73%14.92M | -94.08%10.54M | -4.50%174.65M | -9.84%162.43M | 19.03%180.55M | 5.31%177.91M | 48.74%182.87M | 72.13%180.15M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Adverse Opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Daxin Certified Public Accountants (Special General Partnership) | -- | -- | -- | ZTE Accounting firm (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
